TrialThe Lancet. Infectious diseases2022

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.

Karin Hardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.